Why the study?
Does oral bosentan improve outcomes in patients with pulmonary arterial hypertension?
Does oral bosentan improve outcomes in patients with pulmonary arterial hypertension?
Oral bosentan at 125 mg twice daily is an effective and well-tolerated therapy for pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
May support bosentan 125 mg twice daily in PAH; leaves open confirmation from randomized trials.
Rubin et al. (2002) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: